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A Comprehensive Review Including Personal Experience from Retirement Home Patients
Section 1: Introduction
On my first day at work as a caregiver in a memory care retirement home, I felt a variety
of emotions. I was nervous and devastated at the hardships I saw, but eager and excited to begin
my career in the health field. This job provided me the opportunity to work with the elderly and
get my feet in the door with patient care experience. While it is not always the easiest job, it has
provided me with so much strength and inspiration to continue to develop a career in health care.
Aging is the decline in abilities or loss of adaptation over time resulting from the process
of degeneration (Xia et al., 2018). The changes in abilities are a result of deterioration within the
cells and tissues that lead to impairment of essential cellular functions and eventually death
(Harman, 2001). Within the aging population, there are about six million Americans, around 65
years and older that are diagnosed with Alzheimer’s Disease. This number is expected to grow to
13.8 million by 2060 if a cure is not found. For that reason, Alzheimer’s Disease is one of the
strongest linked diseases that is age-related (“2021 Alzheimer’s disease facts and figures”, 2021).
Unfortunately, the number of individuals affected will continue to increase because there
is no cure. To be more specific, the number of individuals expected to be diagnosed by 2050 is
near 152 million (Breijyeh & Karaman, 2020). From my own personal experience, I have
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become familiar with a small group of these six million Americans. From working in a memory
care unit at a retirement home for several years now, I have become fascinated with
understanding the brain disorder that destroys memory and cognitive abilities slowly over time.
Alzheimer’s Disease is a neurodegenerative illness and disease, the most common type of
dementia, and the sixth leading cause of death (Sá et al., 2012). The disease was discovered in
1906 and named after Dr. Alois Alzheimer, a psychiatrist and neuropathologist. Over time, a
variety of hypotheses have developed regarding the cause behind this multifactorial disease, and
these will be disclosed in a later section. Nonetheless, the disease was first observed in changes
of the brain tissue of a woman who was said to have die from an unusual mental illness with
many abnormal bumps. These bumps are now recognized as tangled bundles of fibers, called
neurofibrillary tangles. Additionally, the woman had a massive loss of neurons around the
cerebral cortex, a major location site for memories and learning skills (Hippius & Neundörfer,
2003). As symptoms were not understood at this time, she was said to have been at a loss for
memory and performing unusual behaviors. My experience in memory care has led me to see the
symptoms often vary greatly. These can include trouble finding the right words, impaired
judgement, visual or spatial awareness, a decline in thinking abilities, asking the same questions
over again, misplacing items, getting lost easily, or even violent lashes that appear in later stages
(Kumar et al., 2021). As I have learned in the memory care unit, Alzheimer’s can look different
for every patient, so the way I approach each patient with care will vary.
AD can occur in two general ways. There are two different onsets to this disease that lie
around 60-65 years as the common differential line based off a sociological perspective and
randomly used for clinical use, rather than biological importance (Sá et al., 2012). The early
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onset form of AD, EOAD, which is extremely rare, results in around 5-10% of cases starting
around age 45. If one is diagnosed with early onset there tends to be a more progressive
treatment pathway with a shorter survival time period (Ayodele et al., 2021). As far as late onset
of AD (LOAD), it remains much more common and can be seen as sporadic, meaning symptoms
could be scattered and there may not be any indication of it progressing. Some of the phenotypic
differences between the onsets is the rate of progression, metabolic deficiency of the parietal and
temporal lobes, division and grade of gray matter atrophy, and the specific allele of the APOE
gene, ę4, is associated with the later onset. The significance of gray matter atrophy relies on how
strong the reduction in cells are of the brain. In early onset, atrophy will be more spread over a
wide area, rather than more localized to a specific area in late onset (Sá et al., 2012).
Section 2: Neuroscience of AD
AD is a disease of the nervous system. The human brain has billions of neurons,
specialized cells that function within the nervous system receiving sensory input that are turned
into motor output through electrical signals. Alzheimer’s disease can either cause a loss of
function and death within the neurons, or the opposite with an abnormal accumulation of
neurons. In other words, there are two main ways that the nervous system is disrupted by the
disease, positive and negative lesions (Breijyeh & Karaman, 2020).
Positive lesions can include any accumulation of neurofibrillary tangles, amyloid plaques,
dystrophic neurites, and neuropil threads. The build up of amyloid plaques are extracellular
deposits of the beta-amyloid (AB) protein surrounded by amplified axonal endings. The AB
protein contributes as a factor causing neurotoxicity and irregular neural function, where it is
derived from the amyloid precursor protein located on chromosome 21, which is a familiar link
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to Alzheimer disease genetically (Kumar et al., 2021). Therefore, the collection and density of
plaques in regions within the brain damages the structures that cause synapses, which is the
electrical signal mentioned. The neurofibrillary tangles as a positive lesion are tangled bundles of
fiber or abnormal bunches of the tau protein inside the cytoplasm, axons, and dendrites of a
neuron that cause a loss of cytoskeletal microtubules (Breijyeh & Karaman, 2020). The function
of the tau protein is to stabilize the axonal microtubules (Kumar et al., 2021). If the neuron was
healthy, their structure consists of microtubules that function along side the cell body, axon, and
dendrites. The tau protein inside these neurons binds to the microtubules allowing them to
remain stable. In AD, Alzheimer’s affected neurons contain tau proteins sticking together
because the microtubules are not able to create that balance with all the chemical changes
occurring in the brain (Breijyeh & Karaman, 2020). In early stages, the accumulation of AB
starts in the neocortical region and then limbic system, but as the disease progresses the
diencephalon, basal forebrain, and cerebellum are affected. On the other hand, tau first affects
the entorhinal cortex and hippocampus (Ayodele et al., 2021).
The negative lesions are the losses of brain matter. These negative legions are a large
atrophy of neural, neuropil, or synaptic loss. Synaptic destruction within the neocortex results in
a loss of memory in the early stages of AD. The losses develop from defects within axonal
transport, mitochondria damage, oxidative stress, and any other functions that impact the
synaptic sites. With the impairment in function, the loss continues to reduction in dendritic
spines, pre-synaptic terminals, and axonal dystrophy. When it comes to diagnosis, these synaptic
proteins can become biomarkers for detection of synaptic loss (Breijyeh & Karaman, 2020).
Section 3: Genetics
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As an autosomal dominant disorder, Alzheimer’s can be completely penetrant when
mutations in specific genes are inherited. In fact, 70% of AD cases are developed from genetic
factors. This disease is connected to mutations in four major genes, Amyloid precursor protein
(APP) on chromosome 21, Presenilin 1 (PSEN1) on chromosome 14, Presenilin 2 (PSEN2) on
chromosome 1, and apolioprotein E (ApoE) on chromosome 19 (Kumar et al., 2021).
APP is a transmembrane protein cleaved by a-, B- and y- secretases in order to release
AB and is encoded by the APP gene on chromosome 21. The mutations within this gene, which
number around 30, cause it to release high amounts of AB that result in accumulation. On the
other hand, there is a protective mutant, A673T that decreases secretions of AB, AB40, and
AB42, working to protect those from AD. All mutations of AB surround the secretes cleavage
site (Breijyeh & Karaman, 2020).
For the PSEN1 and PSEN2 genes, there similarity rate is 67%, with the only variation in
the N-terminus and the hydrophilic region. These proteins lead to aggregation of beta-amyloid
peptide by disrupting the production of gamma-secretase (Kumar et al., 2021). A mutation in the
PSEN2 gene is extremely rare, with around 40 different mutations that have been identified.
However, it is more common in PSEN1, with over 200 mutations identified. PSEN1 is a protein
that triggers the y-secretase complex and once again plays a factor in AB production from APP.
Studies in mice have shown that eliminating this gene can cause synaptic disfunction and
memory loss. The mutation is as simple as a single amino acid substitution, but the result is as
difficult as loss of memory. A mutation in the PSEN1 gene results in an increase in the ratio of
AB42 and AB40 by decreasing only the AB40 level. Contrastingly, PSEN2 mutations are rare
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and have little effect on AB production. If there is an effect it is severe on the AB 42/40 ratio and
a dramatic increase in y-secretase activity (Breijyeh & Karaman, 2020).
The ApoE gene it is located on chromosome 19 with three alleles that consist of ApoE2,
ApoE3, and ApoE4, with again single-nucleotide polymorphisms causing the difference in
coding sequences. ApoE is a glycoprotein that mediates cholesterol in the liver and brain of
astrocytes and microglia. This ApoE protein acts as a receptor-mediated endocytosis ligand for
lipoprotein molecules like cholesterol, while plays a big role in myelin production and normal
brain function. Additionally, ApoE has an affinity for the beta-amyloid protein. Out of all the
isoforms, ApoE4 has been closely associated with EOAD and LOAD. ApoE2 and ApoE3 serve
as a lower risk and even a protective effect (Breijyeh & Karaman, 2020). If only one APOEe4
allele is present then the chances of accumulating the disease are nearly 50%, compared to the
average of 90% with two alleles. Each allele lowers the age disease onset and contributes to the
AB deposition as senile plaques (Kumar et a., 2021).
Section 4: Different Hypotheses behind Alzheimers
As Alzheimer’s Disease is a very complex illness, there are several hypotheses that
explain the possible causes behind this disease. While there is still a lot of information that is
unknown, these hypotheses include the AB cascade or amyloid hypothesis, the tau protein
hypothesis, the inflammation hypothesis, the cholinergic hypothesis, and the glucose hypometabolism hypothesis (Du et al., 2018).
The amyloid hypothesis proposes that the abnormal deposition of B-sheets in the central
nervous system is the cause of AD. This hypothesis serves as the most recognized and has been
the primary reasoning for AD over 25 years now. In patients with AD, the metabolic ability to
6

break down AB is decreased so the peptides accumulate. AB 40 and AB 42 are important
elements to this AB peptide, which represent the number of amino acid residues. Therefore,
when AB 42 is building up, amyloid fibrils begin to turn into senile plaques, which we know will
contribute to neurotoxicity. Going along with that, the APP gene on chromosome 21 can carry
different genetic mutations of APP, which supports this amyloid hypothesis. Mutants in the APP
genes lie near B-secretase or y-secretase cleavage sites, which correlates with the increase in AB
42. However, the amyloid process still brings problems to the table that do not seem to run
parallel with what it is claiming. When investigating this hypothesis, genetically modified mice
were used to look into the effect of AB being deposited in the brain. In the results, senile plaques
were found, but the accumulation of tau protein and nerve cell death had not been seen.
Therefore, the problem with this hypothesis is the idea that AB fibrils are not truly toxic, nor do
they elicit a strong effect on the tau accumulation (Kametani & Hasegawa, 2018).
Moving on, the tau hypothesis holds significance in regard to neurofibrillary tangles,
which are composed of the tau protein. Tau is a protein involved with microtubules that are
behaving as scaffolding proteins in axons (Du et al., 2018). As tau builds up in these tangles, the
accumulation leads to impairing the axons of the neurons. Since a problem was realized within
the AB hypothesis, the tau hypothesis continues to draw more attention to the option of
therapeutic treatments and studies of biomarkers. Going off this hypothesis with a treatment
approach, attempts can consists of blocking of tau aggregation, tau vaccinations, stabilizing
microtubules, or control of the kinases and phosphates that have a role on tau function (Kametani
& Hasegawa, 2018).
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For the inflammation hypothesis, it is proposed that the microglia plays a role in the
pathogenesis of AD. Microglia are immune cells of the central nervous system that are associated
with brain infections and inflammation, and the first cells to respond when something goes
wrong in the brain. Microglia and astrocytes border the amyloid plaques, as they also release
pro-inflammatory cytokines (Du et al., 2018). The natural process of synaptic pruning is also
caused by microglia, where the brain eliminates extra synapses. Therefore, there is evidence to
show that the pruning may get out of control, which results in the extreme loss of synapses and
reduced cognitive function (Cepelewicz, 2016). The action of microglia have been found to be a
sign in a very early stage of the disease. Non-steroid anti-inflammatory drugs (NSAIDs) were
experimented with, but shown to have no impact. With that being said, there is now a high
demand on the need for new biomarkers to assess the function of microglial, in order to further
analyze this hypothesis (Du et al., 2018).
For the cholinergic hypothesis, the concept lies behind acetylcholine, an important
neurotransmitter involved with cholinergic neurons that influence attention span, learning,
memory, sleep, and other sensory information. Since cholinergic neurons were thought to be
damaged, the hypothesis was suggested a role for cholinesterase inhibitors in the development of
AD. The first anti-AD drug, Tacrine, a cholinesterase inhibitor, became available in clinics, until
it was shortly taken down with extreme side effects. Inhibiting cholinesterase only eliminates
some symptoms, but it provides patients with a hope for the future as it slows progression (Du et
al., 2018).
As another early pathogenic concept, there are abnormal metabolic changes that revolve
around the glucose hypo-metabolism hypothesis. Glucose metabolism and ATP formation in the
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brain is found to be reduced in the cerebral cortex. To determine the abnormality in glucose
metabolism, a Positron Emission Tomography (PET) scan can be taken to see this progression.
The glucose hypothesis connects with that of the AB cascade hypothesis because when
glycolysis is reduced in the brain, the decrease in glucose-dependent functions may result in the
build up of AB deposition in those areas (Patil et al., 2012).
Section 5: Diagnostic Abilities
In regards to the diagnostic process for AD, pathological changes can be identified years
before symptoms arise. Not only that, but diagnostic abilities have improved with advances in
technology to examine the molecular aspects with imaging and recognition of biomarkers. As
always, the main exam is the observance of cognitive abilities within the patient and a possible
informer, knowledgable of that person. From a personal point of view, I have seen cognitive
traits change within patients specifically during the time period of COVID-19 when they were
not able to exercise their brain as much without group activities being put into place. Regardless,
supportive evidence from several other biological tests are still accompanied for reassurance.
Aside from the recognition of change within cognitive abilities, checking the levels of
vitamin B12 and folate can inform us of the disease progression. It has been found that a specific
marker with vitamin B12 deficiency has led to the increase in homocysteine levels, which results
in brain damage by oxidative stress, a surge of calcium, and apoptosis. In order to check these
levels, the serum of vitamin B12 and homocysteine levels can be measured, with a blood count
as well (Breijyeh & Karaman, 2020). Within the technology field, imaging methods such as a
Magnetic Resonance Imagining (MRI) can be used to make sure the cognitive impairment is not
a result of any structural abnormalities, along with looking for atrophy in specific lobes of the
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brain. Atrophy in the medial temporal, entorhinal and perirhinal cortex, and the hippocampus
can be a key sign for the disease early along. An MRI has the power to evaluate the hippocampal
volume and predict other volumes that develop from neuronal numbers (Oostveen & Lange,
2021). After such imaging, abnormality in Cerebrospinal fluid (CSF) biomarkers like low
concentrations of AB, increased t-tau or p-tau concentrations, or all can be examined to
determine their effect. CSF total tau (t-tau) is a general marker for neurodegeneration, while
phosphorylated tau (p-tau) serves as a more specific character for AD because neurofibrillary
tangles are often in an abnormal hyper-phosphorylated state (Wattmo et al., 2020). Another
approach to take would be the analyzing of metabolic patterns like hypo-metabolism of glucose
in the lobes with a PET scan. A PET, Positron Emission Tomography, is a scan used to measure
concentrations of molecules in the brain, specifically an abnormal build up. To obtain another
perspective, there is also the examining of autosomal dominant family genetic mutations on
chromosomes 21 (APP), 14 (PSI), and 1 (PS2) (Kumar et al., 2021).
With all the diagnostic techniques available, there is a division of three clinal stages that
help assist the diagnostic process. The first stage, the preclinical stage, marks the pathologic
brain changes, and as mentioned previously can start happening up to years before symptoms
persist. Within this stage, biomarkers of AD can be detected, but are difficult to predict whether
or not it will cause the disease. Following the preclinical stage, Mild Cognitive Impairment
(MCI) takes place exemplifying the memory symptoms that are unusual for ones age, but the
patient still remains independent. The final stage results in the actual disease, Alzheimer’s
dementia, where symptoms are now affecting every day activities and their ability to function on
their own (Kumar et al., 2021). While working in the retirement home for over 4 years now, I
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was able to monitor these stages within a few patients by seeing them switch from the residential
independent side to memory care as their cognitive abilities began to take a toll on their health.
For some, it may happen quickly, but for others it can slowly progress to the point where a
diagnosis or decision is made for their safety and health.
Section 6: Medicine/Treatment
There is no cure available for AD, but there are a variety of treatment options that help
manage the symptoms and progression of the disease. To this day, extensive research continues
to be conducted in search of the cure. As of now, there are three cholinesterase inhibitors and
memantine available to treat the neurotransmitter destruction. In addition, there is an abundance
of therapeutic agents and stem cell therapies that may also play a role in the treatment plan. The
FDA-approved AD cholinesterase inhibitors are currently donepezil, galantamine, and
rivastigmine, followed by the N-methyl-D aspartate (NMDA) antagonist memantine. The
inhibitors work by increasing acetylcholine availability, which restrains its breakdown in
synapse. However, this method of treatment requires caution in individuals with heart problems
because acetylcholinesterase inhibitors (ACHEis) can cause brady-arrhythmias. Memantine is
another possible pathway for symptomatic treatment that works to decrease glutamate excitatory
neurotoxicity without influencing any physiological actions. This approach words best for those
with moderate to severe AD, or together with an ACHEis. Along side the use of these drugs, it is
also important to still treat other mental illnesses within the patient that may be adding to the
overall state of mind. Therefore, depression and anxiety medicine should still be used as needed
since a majority of AD patients are experiencing these illnesses as well. Similarly, antipsychotics
can also be administered in the later stages when the patient may become more aggressive or
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agitated (Lane et al., 2018). From a more general outlook, keeping AD patients in a regular
schedule, challenging the memory they have left, encouraging socialization, and physical
exercise programs helps maintain their wellbeing during this hardship. During my time at home
in the COVID-19 quarantine period, I was able to continuing working in the retirement home,
which allowed me to get a better perspective on the day to day concepts that can benefit the
human brain.
Section 7: Conclusion
All in All, Alzheimers can be very detrimental to not only the patient, but the family and
friends in their life. As cognitive abilities progressively get worse, daily life of the patient
becomes difficult. In the retirement home, my mornings were spent waking up the patients and
taking them through a morning routine that allowed them to be ready for the day. When a patient
wakes up and they are unable to tell you where they are and what they do to get ready, it creates
a devastating impact on the caregiver. For that reason, I have chose to study this disease to learn
more of how I can help and what I can do to make daily life easier for those who are suffering.
Not only that, but I was eager to learn more about why science has yet to find a cure and what
area is lacking in knowledge and research. While this comprehensive review covers only the
general concepts, there is a wide variety of information left to be investigated. As I continue my
career path into the field of health and medicine, I will fight for those struggling with this disease
and provide support to all my patients.
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